1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER
Cachexia
Mayo Clinicprotein_peptidePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Cachexia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ponsegromab Pfizer | Phase 2/3 | BB |
Anamorelin Helsinn Therapeutics (U.S.), Inc | Phase 3 | BB |
MEGESTROL ACETATE IMPURITY B Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 3 | BB |
Nanocrystalline Megestrol Acetate Suspension Nanfang Hospital, Southern Medical University | Phase 3 | BB |
Infliximab Centocor, Inc. | Phase 3 | BB |
View all 29 →
Same molecule, other indications
1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →